Ubs Group Ag Absci Corp Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Absci Corp stock. As of the latest transaction made, Ubs Group Ag holds 714,145 shares of ABSI stock, worth $3.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

714,145

Previous 46,634 1431.38%

Holding current value

$3.57 Million

Previous $178,000 951.12%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.55 - $4.38 $1.7 Million - $2.92 Million	667,511 Added 1431.38%	714,145 $1.87 Million
Q3 2024 Nov 14, 2024	BUY	$2.97 - $4.49 $48,678 - $73,591	16,390 Added 54.19%	46,634 $178,000
Q2 2024 Aug 13, 2024	SELL	$2.92 - $6.58 $258,533 - $582,586	-88,539 Reduced 74.54%	30,244 $93,000
Q1 2024 May 13, 2024	BUY	$3.41 - $5.74 $384,552 - $647,311	112,772 Added 1876.09%	118,783 $674,000
Q4 2023 Feb 09, 2024	BUY	$1.15 - $4.79 $12 - $52	11 Added 0.18%	6,011 $25,000
Q2 2023 Aug 11, 2023	SELL	$1.17 - $2.03 $14,135 - $24,526	-12,082 Reduced 66.82%	6,000 $9,000
Q1 2023 May 12, 2023	BUY	$1.58 - $3.41 $6,215 - $13,414	3,934 Added 27.81%	18,082 $31,000
Q4 2022 Feb 08, 2023	BUY	$2.0 - $3.58 $26,296 - $47,069	13,148 Added 1314.8%	14,148 $29,000
Q2 2022 Aug 10, 2022	SELL	$3.13 - $8.83 $5,277 - $14,887	-1,686 Reduced 62.77%	1,000 $3,000
Q1 2022 May 16, 2022	SELL	$5.87 - $9.46 $1,567 - $2,525	-267 Reduced 9.04%	2,686 $22,000
Q4 2021 Feb 14, 2022	SELL	$7.88 - $18.03 $3,238 - $7,410	-411 Reduced 12.22%	2,953 $24,000
Q3 2021 Nov 15, 2021	BUY	$10.37 - $30.29 $34,884 - $101,895	3,364 New	3,364 $39,000

Others Institutions Holding ABSI

# of Institutions

145

Shares Held

62.8M

Call Options Held

202K

Put Options Held

70.9K

View Full List

About Absci Corp

Ticker ABSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 92,843,504
Market Cap $464M
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....

More about ABSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account